Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.12 EUR
Change Today -0.068 / -35.60%
Volume 0.0
LYF On Other Exchanges
As of 2:08 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

ekf diagnostics holdings plc (LYF) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/1/14 - €0.34
52 Week Low
11/27/15 - €0.12
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

ekf diagnostics holdings plc (LYF) Related Businessweek News

No Related Businessweek News Found

ekf diagnostics holdings plc (LYF) Details

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East and Africa, and internationally. It offers glycated hemoglobin (HbA1c) analyzers, such as Quo-Test, Quo-Lab, and Biosen HbA1c analyzers for monitoring diabetes. The company also provides hemoglobin analyzers, including Hemo Control, a hemoglobin analyzer that provides quantitative lab quality results within 25 seconds for blood banks, hospitals, and clinics; Hemo Vet for veterinary use; STAT-Site, a hand-held hemoglobin analyzer; UltraCrit, a hematocrit measurement device for blood donor screening; HemataSTAT, a microhematocrit system, which offers quantitative hematocrit; and DiaSpect Hemoglobin T and DiaSpect Tm, the hemoglobin measurement systems. In addition, it offers glucose analyzers, such as C-Line GP+, C-Line Clinic, and S-Line Lab+ used in laboratories and sports institutions; and lactate analyzers comprising Biosen C-Line and S-Line glucose and lactate analyzers, as well as Lactate Scout+, a blood lactate analyzer for athletes, coaches, amateurs, and sport scientists. Further, the company provides rapid testing services, including pregnancy tests, such as True20 and QuPID for urine only or urine and serum pregnancy testing; and infectious diseases tests, such as H. Pylori, RELY Mono, RELY, and Strep A for the detection of pathonogenic micro-organisms, such as bacteria, parasites, viruses, and fungi. Additionally, it offers Sepsis testing services; clinical chemistry reagents; and diagnostic biomarker-based enzyme-linked immunosorbent assay kits and rapid tests, as well as maternal and women health diagnostic solutions. The company sells its products to GP surgeries, pharmacies, blood banks, sports clinics, hospitals, and laboratories through a network of distributors. EKF Diagnostics Holdings plc was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

395 Employees
Last Reported Date: 03/16/15
Founded in 1990

ekf diagnostics holdings plc (LYF) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 238.0K GBP
Chief Financial Officer, Finance Director, Se...
Total Annual Compensation: 167.0K GBP
Chief Operating Officer and Executive Directo...
Total Annual Compensation: 184.0K GBP
Deputy Non-Executive Chairman
Total Annual Compensation: 45.0K GBP
Chief Technology Officer and Executive Direct...
Total Annual Compensation: 182.0K GBP
Compensation as of Fiscal Year 2014.

ekf diagnostics holdings plc (LYF) Key Developments

EKF Diagnostics Holdings plc Provides Revenue Guidance for the Full Year Ending December 31, 2015

EKF Diagnostics Holdings plc provided revenue guidance for the full year ending December 31, 2015. For the period, the company expects to achieve full year revenues of approximately £32 million. There are likely to be a number of items which will materially affect the company's profit before tax for the year, including: the partial or complete impairment of the Molecular division. Discussions regarding the divestment or closure of the Molecular division are still ongoing; a provision against, or write off of, specific debtors; and the closure costs of the STI site in Sanford, which the company announced on November 12, 2015.

EKF Diagnostics Holdings Mulls Acquisitions

EKF Diagnostics Holdings plc (AIM:EKF) is seeking acquisitions. "There may be opportunities for strategic acquisitions" said Ron Zwanziger the non-executive Chairman.

EKF Diagnostics Holdings plc Announces Death of Director

EKF Diagnostics Holdings plc announced with regret that Kevin Wilson, Non-Executive Director, passed away peacefully on November 20, 2015 after a short illness.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LYF:GR €0.12 EUR -0.068

LYF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LYF.
View Industry Companies

Industry Analysis


Industry Average

Valuation LYF Industry Range
Price/Earnings 18.9x
Price/Sales 1.0x
Price/Book 0.5x
Price/Cash Flow 6.5x
TEV/Sales 1.0x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact EKF DIAGNOSTICS HOLDINGS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at